Condition 1: nausea and vomiting. Condition 2: adverse reaction. Nausea with vomiting, unspecified Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients were treated with triple antiemetic therapy comprising oral administration of 125 mg Aprepitant and intravenous injection of 12 mg Dexamethasone, and 8mg O
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Cancer patients receiving moderate emetogenic chemotherapy regimens,formed the study cohort. Eligible patients were adults (aged between 18 - 70 years) with a karnofsky index of 50% or more). Women at reproductive ages should had undertaken an appropriate contraceptive method
Exclusion criteria
Exclusion criteria: causes of nausea or vomiting unrelated to the chemotherapy (e.g., gastrointestinal obstruction, massive ascites, widespread brain metastases, history of motion sickness or vestibular dysfunction, uremia or electrolyte disturbance) active infection uncontrolled seizure candidate for radiation therapy of brain or upper abdomen in less than a week an emetic episode 24 h before initiation of chemotherapy complications that prohibited Dexamethasone use one of the followings observed in their lab studies : wbc2.5 * upper limit of normal,Bill & Cr > 1.5* upper limit of normal opium addicted poor compliance receiving corticosteroids for more than 3 months and more than 50 mg Prednisone daily; Carlson’s comorbidity scale of 3 or more Any drugs with antiemetic efficacy other than the study drugs wouldn’t been allowed before the study started, and were recorded on.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients experiencing nausea and vomiting with MSKCC questionnaire. Timepoint: day 1 and 5 of chemotherapy. Method of measurement: MSKCC nausea and vomiting questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response. Timepoint: day 1 and day 5 of chemotherapy. Method of measurement: MSKCC nausea and vomiting questionnaire.;Complete control. Timepoint: day 1 and day 5 of chemotherapy. Method of measurement: MSKCC nausea and vomiting questionnaire.;Overall response. Timepoint: day 1 and day 5 of chemotherapy. Method of measurement: MSKCC nausea and vomiting questionnaire.;Resistance to treatment. Timepoint: day 1 and day 5 of chemotherapy. Method of measurement: MASCC nausea and vomiting questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMania Rajabzadeh Kheradmardi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed